Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA
Main finding · Discontinuation of etanerceptResult — go to the resultHazard ratio 1.06 95% CI 0.89–1.26Authors' conclusion
This is the largest matched comparative effectiveness analysis showing patients switching from etanercept originator to biosimilar appearing to do just as well with regard to disease activity and drug persistence compared with those who remained on the originator.
Study context
- Population
- Adults with RA in the BSRBR-RA switched from etanercept originator to biosimilar in non-medical/cost-saving switchingmatched cohort
- Exposure
- Switch from etanercept originator to biosimilar vs remaining on originator
- Biosimilarn = 1,024
- Outcome
- Drug survival (discontinuation of etanercept)
Methodological detailsmatched on gender, age, disease duration and originator start year, Cox proportional hazard models, multiple imputation, comparative effectiveness
- Matched on gender, age, disease duration and originator start year
- Cox proportional hazard models
- Multiple imputation
- Comparative effectiveness
Main finding
Discontinuation of etanercept
Hazard ratio
1.06
95% CI 0.89–1.26
Biosimilarvs Originator
HR 1.06 (95% CI 0.89–1.26)
As reported in the abstract
- Patients remaining on treatment at three years
- 65%
Observational data: associations, not effects.
Further findings
Switch back to the originator · within the first year
- Patients switched back to the originator within the first year
- 95 (9%)
Worsening of DAS28 (>0.6 units) · 6 months and 12 months
- Biosimilar patients no more likely to have a worsening of DAS28 (>0.6 units) vs those who remained on the originator
Original publication
Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA. Rheumatology (Oxford). Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →